At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Effect of Sitagliptin on the Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers
In Brief
A Phase 4 clinical trial evaluating Sitagliptin and placebo for Healthy and Type 2 Diabetes. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Type 2 Diabetes
CountriesSweden
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartAug 2009
Primary CompletionMay 2011
Study CompletionSep 2012
TodayJul 2026
First PostedApr 22, 2009
Enrollment StartAug 1, 2009
Primary CompletionMay 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.2 years ago
Interventions
Sitagliptindrug
100 mg sitagliptin before ingestion of macronutrient
placebodrug
A placebo tablet is given before ingestion of macronutrients